PCNT Point of Care Nano Technology Inc (CE)

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of

The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): December 26, 2024 (December 20, 2024)

 

 

Point of Care Nano-Technology, Inc.

(Exact name of registrant as specified in its charter)

 

Nevada		000-56356		27-2830681
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

 

531 US HWY 22 East, Suite 232, Whitehouse Station, NJ 08889
(Address of principal executive offices)

 

(732) 723-7395

(Registrant's telephone number, including area code)

 

109 AmberSweet Way, Davenport, FL, 33897

(Former name or former address, if changed since last report.)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

o	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

o	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act: None 

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

Emerging Growth Company o

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

 

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

Effective December 20, 2024, Nichlas DeVito resigned as Chief Executive officer, President, Treasurer, Secretary and Chairman and Director of Point of Care Nano-Technology, Inc. (the “Company”). Mr. DeVito’s resignation was not due to any disagreement relating to financial matters with the Board of Directors, the management or the auditors of the Company. Also effective as of December 20, 2024, Mr. DeVito entered into a Mutual Release of Claims Agreement a copy of which is attached hereto as Exhibit 10.1.

 

Effective December 20, 2024, the Board of Directors of the Company appointed Dr. Raouf Guirguis, a current director of the Company, to serve as Chief Executive officer, President, Treasurer and Secretary of the Company.

 

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits. The following exhibits are filed as part of this report:

 

Exhibit No.		Description of Exhibit
10.1		Mutual Release of Claims Agreement
104		Cover Page Interactive Data File (the cover page XBRL tags are embedded within the inline XBRL document)

 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

	POINT OF CARE NANO-TECHNOLOGY, INC.
Date:  December 26, 2024	/s/ Dr. Raouf Guirguis
	Name: Dr. Raouf Guirguis
	Title: Chief Executive Officer

 

 

 

Exhibit 10.1

 

MUTUAL RELEASE OF CLAIMS AGREEMENT

THIS MUTUAL RELEASE OF CLAIMS AGREEMENT (“Release”), dated effective as of December 20, 2024 (the “Effective Date”), is by and among Point of Care Nanotechnology, Inc., a Nevada corporation (“PCNT”), with a business address in Davenport, Florida and its officers, directors, affiliates, and advisors, (collectively, the “PCNT Parties”) and Nicholas DeVito with residence in Whitehouse Station, NJ, (“DeVito”). All signatories to this Release are sometimes collectively referred to as the “Parties” and individually referred to as “Party”.

WHEREAS, the PCNT Parties engaged DeVito as its Chief Executive Officer and interim Chief Financial Officer in April 2021 and PCNT has determined that it needs to hire executive officers with Life Science experience to continue its growth. PCNT also asks Mr. DeVito to continue as an advisor to the company to ensure a smooth transition.

WHEREAS, PCNT recognizes DeVito’s contributions to the business and thanks him for his service to the company.

WHEREAS, the Parties desire to require each other to enter into this Release and confirm the absence of (i) any claims by the PCNT Parties against the DeVito and/or any of their respective affiliates and (ii) any claims by the DeVito against the PCNT Parties and/or any of their respective affiliates; and

WHEREAS, the PCNT Parties and DeVito acknowledge each are relying on this Release.

NOW, THEREFORE, in consideration of the premises contained herein, the consideration set forth in the Agreements and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties hereby agree as follows:

Section 1.                Consideration. Consulting on growth opportunities for the PCNT business may be requested at a future compensation rate to be determined by the Parties.

Section 2.                Transition. DeVito agrees to step down as Director, Chief Executive Officer and Chief Financial Officer on December 20, 2024 and effective as of December 20, 2024 will no longer act as an officer or Director of PCNT in any capacity. PCNT also requests Mr. DeVito be available for additional consulting related to assisting PCNT with its SEC filings for a a consulting fee of $10,000.00 per month following the date of this Agreement.

Section 3.                Release – PCNT Parties. Each PCNT Party hereby RELEASES and FOREVER DISCHARGES DeVito and his affiliates from all manners of action, causes of action, suits, debts, sums of money, accounts, bonds, bills, covenants, contracts, controversies, agreements, premises, variances, damages, judgments, executions, claims and demands whatsoever in law or in equity (collectively, the “Claims”) which he/it ever had, now has, or hereafter can, shall or may have against DeVito and/or any of their affiliates in respect of any and all agreements, obligations and events incurred or occurring on or prior to the date hereof, including without limitation: (i) Claims by any PCNT Party for reimbursement or contribution of expenses under the Agreements, (ii) Claims by any of the PCNT Parties with respect to payment of any kind either in cash, property or securities, (iii) Claims by any of the PCNT Parties with respect to any breach or violation of the Agreements and (iv) Claims by any of the PCNT Parties with respect to violation of any trade secrets, patent infringement or otherwise. Each PCNT Party further agrees not to file or bring any claim, suit, civil action, complaint, arbitration or administrative action in any city, state or federal court or agency or arbitration tribunal with respect to any Claim against DeVito or any person. None of the PCNT Parties has transferred any Claim to any third party.

 Section 4.                Release – DeVito. DEVITO hereby RELEASES and FOREVER DISCHARGES the PCNT Parties and their affiliates from all Claims apart from continuing employment obligations and corporate officer indemnification obligations of PCNT which he/it ever had, now has, or hereafter can, shall or may have against any or all of the PCNT Parties and/or any of their affiliates in respect of any and all agreements, obligations and events incurred or occurring on or prior to the date hereof, including without limitation: (i) Claims by any DEVITO Party for reimbursement or contribution of expenses under the Agreements, (ii) Claims DeVito with respect to payment of any kind either in cash, property or securities, (iii) Claims by DeVito with respect to any breach or violation of the Agreements and (iii) Claims the DeVito with respect to violation of any trade secrets, patent infringement or otherwise. Each DEVITO Party further agrees not to file or bring any claim, suit, civil action, complaint, arbitration or administrative action in any city, state or federal court or agency or arbitration tribunal with respect to any Claim against the PCNT Parties or any person. DeVito has not transferred any Claim to any third party.

Section 5.            Mutual Non-Disparagement. The PCNT Parties agree and shall use their best efforts to cause its respective executive officers and directors to agree, that they will not make or publish any statement critical of DeVito, or in any way adversely affecting or otherwise maligning DeVito’s reputation. DeVito agrees that he or she will not make or publish any statement critical of PCNT, its affiliates and their respective executive officers and directors, or in any way adversely affecting or otherwise maligning the business or reputation of PCNT, its affiliates and subsidiaries and their respective officers, directors and employees. PCNT agrees that any document or public filing that includes DeVito’s name will require the consent of both parties before publishing.

Section 6.                Competency. Each Party acknowledges that he/it fully comprehends and understands all of the terms of this Release and their legal effects. Each Party hereby further expressly warrants that he/it is competent to execute this Release, that he/it is executed knowingly and voluntarily and without reliance upon any statement or representation of any released party or its representatives, and that he/it has consulted with an attorney of his/its choice regarding this Release.

Section 7.                Successors. This Release shall be binding upon each Party and his/its heirs, devisees, administrators, executors, personal representatives, successors and assigns and shall inure to the benefit of the PCNT Parties or DeVito, respectively and their respective affiliates and each of their respective successors and assigns.

Section 8.                Governing Law and Venue. This Release shall be governed by and construed in accordance with the laws of the state of New Jersey without giving effect to principles of conflicts of laws and that New Jersey State shall be the only appropriate Venue for any disputes arising from this agreement.

Section 9.                Modification. This Release may be modified only by a written instrument executed by all Parties.

Section 10.            Severability. If any provision of this Release is held to be illegal, invalid or unenforceable under present or future laws, such provision shall be fully severable and this Release shall be construed and enforced as if such illegal, invalid or unenforceable provision never comprised a part hereof; and the remaining provisions hereof shall remain in full force and effect and shall not be affected by the illegal, invalid or unenforceable provision, and there shall be added automatically as part of this Release a provision as similar in its terms to such illegal, invalid or unenforceable provision as may be possible and be legal, valid and enforceable.

Section 11.            Indemnification. PCNT agrees to indemnify DeVito against any action, suit, claim, or proceeding, whether civil, criminal or administrative, and against any fine, cost, levy, expense, judgment or award arising from such claim, in which DeVito may be involved in any capacity as a result his past or future service to PCNT, or any application, filing, submittal, etc., by DeVito.  PCNT shall defend at its cost and hold that DeVito shall have no responsibility to verify the accuracy or sufficiency of any statement, document, material, or information provided by PCNT, or by any agent acting on PCNT’s behalf.

Section 12.            IN WITNESS WHEREOF, each Party has executed this Release effective as of the date first above written.

 

Point of Care Nano Technology, Inc

 

By:	/s/ Raouf Guirguis		By:	/s/ Nathan Keele
	Name: Raouf Guirguis			Name: Nathan Keele
	Title: Director			Title: Director
NICHOLAS DEVITO
By:	/s/Nicholas DeVito
	Name: /s/Nicholas DeVito

  

 

v3.24.4

Cover	Dec. 20, 2024
Entity Addresses [Line Items]
Document Type	8-K
Amendment Flag	false
Document Period End Date	Dec. 20, 2024
Entity File Number	000-56356
Entity Registrant Name	Point of Care Nano-Technology, Inc.
Entity Central Index Key	0001504239
Entity Tax Identification Number	27-2830681
Entity Incorporation, State or Country Code	NV
Entity Address, Address Line One	531 US HWY 22 East
Entity Address, Address Line Two	Suite 232
Entity Address, City or Town	Whitehouse Station
Entity Address, State or Province	NJ
Entity Address, Postal Zip Code	08889
City Area Code	(732)
Local Phone Number	723-7395
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Entity Emerging Growth Company	false
Former Address [Member]
Entity Addresses [Line Items]
Entity Address, Address Line One	109 AmberSweet Way
Entity Address, City or Town	Davenport
Entity Address, State or Province	FL
Entity Address, Postal Zip Code	33897

---